| Lmc Idtf Lexington | |
|
811 W Main St Lexington SC 29072-2507 | |
| (803) 358-6100 | |
| Not Available |
| Full Name | Lmc Idtf Lexington |
|---|---|
| Speciality | Clinic/Center |
| Location | 811 W Main St, Lexington, South Carolina |
| Authorized Official Name and Position | Jeffrey Brillhart (SENIOR VP/CFO) |
| Authorized Official Contact | 8037912967 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Lmc Idtf Lexington Po Box 6069 West Columbia SC 29171-6069 Ph: () - | Lmc Idtf Lexington 811 W Main St Lexington SC 29072-2507 Ph: (803) 358-6100 |
| NPI Number | 1275130650 |
|---|---|
| Provider Enumeration Date | 10/08/2020 |
| Last Update Date | 10/12/2020 |
| Medicare PECOS PAC ID | 2567872070 |
|---|---|
| Medicare Enrollment ID | O20210125000972 |
News Archive
With the world in the grip of a global pandemic, health misinformation has become a matter of life or death. But using audio dramas delivered on WhatsApp to explicitly address falsehoods could help Africa tackle this scourge, a study suggests.
Two common operations for stress urinary incontinence help women achieve similar levels of dryness, according to a team of urologists and urogynecologists who compared the treatments in a large U.S. trial supported by the National Institutes of Health. The study is being released online May 17, 2010, by the New England Journal of Medicine to coincide with a presentation at the annual meeting of the American College of Obstetrics and Gynecology. Results will appear in the June 3 print edition.
A new Tofu-based biomaterial that can help mend broken bones and damaged tissues is being developed thanks to an investment of £149,000 from NESTA (the National Endowment for Science, Technology and the Arts), the organization that champions UK creativity and innovation.
Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on August 10, 2011 to discuss the CMC, pharmacology, toxicology, and clinical plans for Advaxis PSA, its construct to fight prostate cancer.
Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT®) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY®) as the sole active ingredients for the maintenance treatment of people living with Human Immunodeficiency Virus (HIV).
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275130650 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QM1300X | Clinic/center - Multi-specialty | (* (Not Available)) | Secondary |
| 261QR0200X | Clinic/center - Radiology | (* (Not Available)) | Primary |
News Archive
With the world in the grip of a global pandemic, health misinformation has become a matter of life or death. But using audio dramas delivered on WhatsApp to explicitly address falsehoods could help Africa tackle this scourge, a study suggests.
Two common operations for stress urinary incontinence help women achieve similar levels of dryness, according to a team of urologists and urogynecologists who compared the treatments in a large U.S. trial supported by the National Institutes of Health. The study is being released online May 17, 2010, by the New England Journal of Medicine to coincide with a presentation at the annual meeting of the American College of Obstetrics and Gynecology. Results will appear in the June 3 print edition.
A new Tofu-based biomaterial that can help mend broken bones and damaged tissues is being developed thanks to an investment of £149,000 from NESTA (the National Endowment for Science, Technology and the Arts), the organization that champions UK creativity and innovation.
Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on August 10, 2011 to discuss the CMC, pharmacology, toxicology, and clinical plans for Advaxis PSA, its construct to fight prostate cancer.
Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT®) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY®) as the sole active ingredients for the maintenance treatment of people living with Human Immunodeficiency Virus (HIV).
› Verified 3 days ago
Baird Transitions Mht Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 317 Ruth Vista Road, Lexington, SC 29073 Phone: 469-307-5822 | |
Twelve Mile Creek Family Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4711 Sunset Blvd, Lexington, SC 29072 Phone: 803-356-3609 Fax: 803-356-3941 | |
Advantage Integrated Medical Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1926 S Lake Dr, Lexington, SC 29073 Phone: 803-462-5440 | |
Lexington Family Practice Lexington Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 122 Powell, Lexington, SC 29072 Phone: 803-957-8400 Fax: 803-957-1939 | |
Lakeview Family Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1316 N Lake Dr, Lexington, SC 29072 Phone: 803-358-1191 | |
Lexington Family Practice White Knoll Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5535 Platt Springs Rd, Lexington, SC 29073 Phone: 803-951-1880 Fax: 803-951-0384 | |
Green Transitions Mht Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 317 Ruth Vista Rd, Lexington, SC 29073 Phone: 972-616-4932 Fax: 877-489-3949 |